United States Uses in Term Clause

Term from Executive Employment Agreement

This EXECUTIVE EMPLOYMENT AGREEMENT (this "Agreement") is entered into this 3rd day of March, 2017 (the "Effective Date") by and between Link Media Holdings, LLC, a Delaware limited liability company ("Company"), and James A. McLaughlin ("Executive").

Term. The term of this Agreement shall commence on March 3, 2017 (the "Commencement Date") and shall continue until Executive's employment under this Agreement is terminated as provided below (the "Employment Term"); provided that, Executive's employment under this Agreement is contingent upon: (i) Company obtaining a satisfactory background check and positive reference checks with respect to Executive; (ii) Company obtaining satisfactory documentation regarding Executive's legal authorization to work in the United States; and (iii) Executive's written acknowledgement and agreement to abide by Company's employee handbook and ethics policy. By signing this Agreement, Executive hereby consents to the release of applicable background and reference check information to Company. Executive's employment may be terminated upon the first to occur of the following events:

Term from Employment Agreement

THIS EMPLOYMENT AGREEMENT (this Agreement) is made and entered into effective as of the 1st day of December, 2012 among FREEDOMROADS, LLC, a Minnesota limited liability company (the Company), and ROGER NUTTALL, an Illinois resident (Employee).

Term. Subject to termination of Employees employment pursuant to Section 7 below, the initial term of Employees employment hereunder shall be for a period of five (5) years commencing as of the date of this Agreement and, upon the expiration of the initial term hereof, shall be automatically renewed for successive three (3) year periods unless either party desires to cancel this Agreement after the initial term or renewal periods, then it shall give the other party written notice of its intent to cancel at least 90 days prior to the expiration of the initial term or any renewal period thereof. The term of Employees employment under this Agreement shall be defined as the Term. Position and Duties. 3.01 Title. During the Term, Employee agrees to serve as the Companys President and Chief Financial Officer or such other position as may be determined by the Company and undertake such additional duties as provided in Section 3.02 below. 3.02 Duties. During the term of this Agreement, Employee agrees to serve the Company, and the Company agrees to employ the Employee as President and Chief Financial Officer or such other position as may be determined by the Company, and Employee will faithfully and to the best of his ability discharge his duties and will devote his full time during business hours for the Company and to the business and affairs of the Company. Employee hereby confirms that during the term of this Agreement, he will not render or perform services for any other corporation, firm, entity or person. In addition, Employee understands that the Companys Chairman, Vice Chairman or Board of Directors may, from time to time, direct that Employee assist and provide other services to the Company or one or more other entities (the Affiliates) directly or indirectly owned or controlled by Stephen Adams, whose trust is the indirect controlling shareholder of the Company on the date hereof, or their successors, heirs, beneficiaries or assigns (Adams). Employee recognizes that he will be required to travel to perform certain of his duties. Notwithstanding the foregoing, Employee shall be permitted to participate in, and be involved with, such community, educational, charitable, professional, and religious organizations so long as such participation does not, in the judgment of the Companys Board of Governors, significantly interfere with the performance of Employees duties hereunder. 4. Compensation. 4.01 Base Salary. During the term of this Agreement, the Company shall pay to Employee a base annual salary of Two Hundred Fifty Thousand and No/100 Dollars ($250,000) (Base Salary), which salary shall be paid in accordance with the Companys normal payroll procedures and policies. 4.02 Incentive Compensation. During the term of this Agreement and subject to the continued employment of Employee by the Company through the date on which payment of the Incentive Compensation (as defined below) is due, the Company shall pay to Employee Incentive Compensation equal to seven tenths of one percent (.7%) (the Applicable Percentage) of the combined EBITDA (as defined below) of the Company and Good Sam Enterprises, LLC (Good Sam), an affiliate of Company, for each calendar year or portion thereof during the Term of this Agreement (Incentive Compensation). As used herein, EBITDA shall mean (i) the combined net income of the Company and Good Sam derived from the ongoing business operations of each such entity for such period plus, to the extent deducted in the determination of net income, interest (other than interest for floor plan financing), federal and state income taxes (or any provision for such taxes), depreciation and amortization and (ii) to the extent not otherwise reflected in net income for purposes of determining EBITDA, gains on the sale of real property by FR or Good Sam or any of their respective subsidiaries, including, without limitation, deferred gains on sale leaseback transactions. Net income shall be determined on the accrual method of accounting and in accordance with generally accepted accounting principles consistently applied, provided that (i) extraordinary items of revenue or expense, as determined by the chief financial officer (including revenue or expense from non-operating investments, revenue or expense from the sale or purchase of assets not in the ordinary course of business or revenue or expense not derived from normal business operations), shall not be reflected in net income, and (ii) amounts paid or received in settlement of (or payment of judgments in respect of) litigation which did not arise in the ordinary course of the business operations of such entity or entities or any of their respective subsidiaries, shall not be reflected in net income. The Incentive Compensation will be paid in monthly draws based on the Companys estimated combined EBITDA for the applicable calendar year, subject to adjustment up or down from time to time by the Company based on actual results compared to estimates and a

Term from Stockholders Agreement

This STOCKHOLDERS AGREEMENT, dated as of May 4, 2016 (this Agreement), is by and between Atlas Air Worldwide Holdings, Inc., a Delaware corporation (the Company), and Amazon.com, Inc., a Delaware corporation (Amazon).

Term. This Agreement shall be effective as of the date hereof and shall automatically terminate upon the date that the Beneficial Ownership of Amazon (directly or through any of its Permitted Transferees), in the aggregate, of the Company Common Stock is less than two percent (2%) of the issued and outstanding shares of Company Common Stock, with the number of shares of Company Common Stock issued and outstanding being calculated on a fully diluted basis, so long as, as of such date, all of the then-remaining Registrable Securities Beneficially Owned by Amazon may be sold in a single transaction without limitation under Rule 144 under the Securities Act; provided, however, that, unless otherwise agreed to by the parties, this Agreement shall in no event terminate prior to the occurrence of an Amazon Investor Rights Termination Event. If this Agreement is terminated pursuant to this Section 6.1, this Agreement shall become void and of no further force and effect, except for the provisions set forth in Section 1.1(e) (Composition of Board of Directors), Section 1.6(d) (Information Rights) (which shall survive termination of this Agreement for a period of two (2) years), Section 4.9 (Miscellaneous), Section 5.2 (Interpretation) and this Article VI (Miscellaneous), and except that no termination hereof shall have the effect of shortening the Standstill Period to the extent that the Standstill Period would continue in effect in the absence of such termination.

Term from License Agreement

THIS LICENSE AGREEMENT (this Agreement) is made and entered into as of the date last signed by a party below (the Effective Date), by and between Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (BMS), and Eiger BioPharmaceuticals, Inc., a Delaware corporation, with offices at 350 Cambridge Ave, Suite 350, Palo Alto, CA 94306 (Eiger). BMS and Eiger are sometimes referred to herein individually as a Party and collectively as the Parties.

Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, shall expire on a country-by-country basis and Licensed Product-by-Licensed Product basis, upon the expiration of the Royalty Term with respect to a given Licensed Product in the applicable country.

Term from License Agreement

THIS LICENSE AGREEMENT (this Agreement) is made and entered into as of the date last signed by a party below (the Effective Date), by and between Bristol-Myers Squibb Company, a Delaware corporation headquartered at 345 Park Avenue, New York, New York 10154 (BMS), and Eiger BioPharmaceuticals, Inc., a Delaware corporation, with offices at 350 Cambridge Ave, Suite 350, Palo Alto, CA 94306 (Eiger). BMS and Eiger are sometimes referred to herein individually as a Party and collectively as the Parties.

Term. This Agreement shall commence as of the Effective Date and, unless sooner terminated in accordance with the terms hereof or by mutual written consent, shall expire on a country-by-country basis and Licensed Product-by-Licensed Product basis, upon the expiration of the Royalty Term with respect to a given Licensed Product in the applicable country.

Term from Intercreditor Agreement

This INTERCREDITOR AGREEMENT, dated as of 25th day of April, 2016 (this "Agreement"), is among Worldwide Stock Transfer, LLC (the "Indenture Trustee") and Webster Business Credit Corporation ("Webster").

Term. This Agreement shall continue until the first date on which either the MBC Obligations or the Issuer's Obligations are indefeasibly paid in full in cash and Webster's commitments to lend under the Credit Agreement have irrevocably terminated.

Term from Incentive Plan

Term. This Plan will be effective as of January 1, 2015, unless earlier terminated pursuant to Section 7.1. II. DEFINITIONS For purposes of the Plan, the following terms will have the meanings set forth below: "Award" means an annual incentive award payable with respect to a Plan Year determined in accordance with Article IV hereof, payable in cash. "Base Compensation" means the base rate of salary payable to a Participant as most recently reflected on the books and records of the Company or any of its subsidiaries, exclusive of bonus, commission, fringe benefits, employee benefits, expense allowances and other nonrecurring forms of remuneration. "Board" means the Board of Directors of the Company. "Chief Executive Officer" means the Chief Executive Officer of the Company. "Committee" means the Compensation Committee of the Board. "Company" means Ormat Technologies, Inc., a Delaware corporation. "Company Performance Metrics" means the Company performance metrics set forth in Appendix A hereto. "Code" means the United States Internal Revenue Code of 1986, as amended. "Participant" means any employee of the Company or any of its subsidiaries who is selected to participate in the Plan pursuant to Article III hereof. Any leased employee, including a leased employee within the meaning of Code Section 414(n) and any person hired as a consultant or independent contractor or any other individual whom the Company or any of its subsidiaries does not treat as its employee for income tax purposes (as applicable), even if it is subsequently determined by a court or administrative agency that such individual should be, or should have been, properly classified as a common law employee of the Company or any of its subsidiaries, will not be a Participant under the Plan.

Term from Manufacturing and Supply Agreement

This MANUFACTURING AND SUPPLY AGREEMENT (this Agreement) dated as of July 31, 2015 (the Effective Date) is made by and between Flexion Therapeutics, Inc., a Delaware corporation having its principal place of business at 10 Mall Road, Suite 301, Burlington, Massachusetts, United States (Flexion) and Patheon UK Limited, a company incorporated in England and Wales having its principal place of business at Kingfisher Drive, Covingham, Swindon, SN35BZ, United Kingdom (Patheon). Flexion, and Patheon are sometimes referred to herein individually as a Party and collectively as the Parties.

Term. This Agreement shall commence as of the Effective Date and, unless earlier terminated in accordance with the terms hereof, shall expire on the tenth (10th) anniversary of the FDA Approval Date (the Initial Term). Notwithstanding, by mutual agreement the Parties may commence discussions three (3) years prior to the end of the Initial Term with a view to extending the Initial Term for such period or periods as may be agreed (collectively, the Initial Term and any extensions thereof, the Term).

Term from Employment Agreement Between

This employment agreement (Agreement) sets out the terms and conditions upon which the Company offers you employment with it whilst employed in The Netherlands for the Term specified below. This Agreement is made with reference to that certain letter and offer of employment, dated 30 October 2015 (Offer Letter), and issued with regard to your employment within the LyondellBasell Group.

Term. Your employment pursuant to this Agreement is intended to be for a definite term of one year (the Term), subject to termination in accordance with section 10 below and the requirements of applicable law. The Agreement ends by operation of law, without notice being required, at the end of the Term. The Term may be shortened or extended at the sole discretion of the Company, depending on the timing of your success in obtaining lawful authorization for eligibility to work in the United States and the actual transfer of your employment to Houston, Texas, as anticipated pursuant to the Offer Letter. In any event, this Agreement will end as of the date that you obtain lawful authorization to work in the United States. You will at that point in time transfer your employment to Houston, Texas in accordance with the terms and conditions set forth in the Offer Letter.

Term from Employment Agreement

This EMPLOYMENT AGREEMENT (Agreement) is entered into as of the Effective Date (as defined below), by and between Sagent Pharmaceuticals, Inc., a Delaware corporation (the Employer or the Company), and Allan Oberman, an individual (the Executive).

Term. The initial term of employment under this Agreement shall be for a three-year period commencing on the later of (a) September 1, 2015 or (b) the date the Executive obtains lawful immigration and work status in the United States, which date shall occur no later than November 15, 2015 (such date, the Effective Date, and such initial term of employment, the Initial Term). The term of employment shall be automatically extended for an additional consecutive 12-month period (the Extended Term) on the third anniversary of the Effective Date and each subsequent anniversary thereof, unless and until the Employer or Executive provides written notice to the other party in accordance with Section 14 hereof not less than 60 days before such anniversary date that such party is electing not to extend the term of employment under this Agreement (Non-Renewal), in which case the term of employment hereunder shall end as of the end of such Initial Term or Extended Term, as the case may be, unless sooner terminated as hereinafter set forth. Such Initial Term and all such Extended Terms are collectively referred to herein as the Employment Period. Anything herein to the contrary notwithstanding, if on the date of a Change in Control the remaining term of the Employment Period is less than 24 months, the Employment Period shall be automatically extended to the end of the 24 month period following such Change in Control.